![MSK medical oncologist Loren Michel](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/124912/3x2/michel_1200x800.jpg?h=10d202d3)
Loren Scott Michel, MD
Head and Neck Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Head & Neck Medical Oncology
- Squamous Cell Carcinoma of the Skin
- Targeted Therapy
Request an Appointment
About Me
- Associate Attending Physician
I am a medical oncologist who cares for people with head and neck cancers, including squamous cell carcinoma and thyroid cancer.
I see about 400 patients each year at Memorial Sloan Kettering Basking Ridge and Memorial Sloan Kettering Nassau. I have nearly 20 years of experience and am committed to helping my patients fight and beat cancer. There is nothing more meaningful to me in life than this pursuit.
Read more
I specialize in treating squamous cell cancer of the mucosal surfaces, including the lips, mouth, throat, voicebox, and nasopharynx. I am particularly interested in treating patients whose tumors are caused by smoking or viruses, such as HPV and the Epstein-Barr virus.
I also have expertise in caring for people with squamous cell carcinoma of the skin. This is a common type of skin cancer that can be deadly if it recurs or spreads to other parts of the body. Incurable squamous cell carcinoma of the skin is rare, but I have extensive experience in treating patients whose disease can’t be cured with surgery or radiation.
I spend a lot of time thinking about the best treatment approach for each patient. It’s critical to find options that will maximize the chance of a cure and minimize side effects. For my patients who have incurable disease, I especially weigh the potential of therapies that will prolong life or reduce symptoms against any side effects. Quality of life always comes first.
The goal of my research is to develop new treatment approaches for head and neck squamous cell carcinoma. We recently published the results of the first trial of palbociclib for treating head and neck cancer. Palbociclib is a pill that targets a specific genetic defect that is found in nearly all HPV-unrelated squamous cell cancers of the head and neck. This drug is likely to provide a significant benefit for the treatment of incurable head and neck squamous cell cancer. My long-term goal is to develop more of these types of therapies that will help improve cure rates.
A head and neck oncologist is a cancer doctor with special training in head and neck cancers. This includes cancers of the larynx, lips, mouth, nose, salivary glands, and throat.
My Specialties
- Head & Neck Medical Oncology
- Squamous Cell Carcinoma of the Skin
- Targeted Therapy
Education
- MD, Case Western Reserve University
Residencies
- Internal Medicine - Mount Sinai School of Medicine
Awards and Honors
- Memorial Sloan Kettering Cancer Center Clinical Scholars Award
- AACR-Sidney Kimmel Foundation for Cancer Research Fellowship in Basic Research
- Damon Runyon Cancer Research Foundation Clinical Investigator Award
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Michel sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Michel
- A Phase III Study of Penpulimab or Placebo Plus Chemotherapy in People with Recurrent or Metastatic Nasopharyngeal Carcinoma
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Oral Oncology, Michel, L. et al 2016: Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Visit PubMed for a full listing of Dr. Michel’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Loren Scott Michel discloses the following relationships and financial interests:
-
KisoJi Biotechnology Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].